The diffused presence of fat within the pancreas was the single most important driver for diseases of both the exocrine pancreas and endocrine pancreas, a recent study reported.
In patients with severe hypertriglyceridemia who are at risk for acute pancreatitis, the drug brought about triglyceride reductions of more than 50% in the phase 2 SHASTA-2 study.
In patients with severely elevated triglyceride levels at risk for developing acute pancreatitis, the investigational drug plozasiran reduced triglyceride levels by an average of 74% after 24 weeks of use without causing any significant safety concerns, according to research presented at the American College of Cardiology's Annual Scientific Session.
1. Post-ERCP pancreatitis was more common in the indomethacin alone group compared to indomethacin plus stent group. 2. The benefit of stent placement was prominent among patients at high risk for pancreatitis. Evidence Rating Level: 1 (Excellent) Study Rundown: In high-risk patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), combining rectal indomethacin with prophylactic pancreatic stent placement